Breakthrough Therapies Act

United States117th CongressS-5123Senate
Updated: Nov 17, 2022

Summary

Breakthrough Therapies Act This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.

Bill texts

Available versions
Introduced (Senate)View official text

1 version available

All available records shown.

Timeline

  1. Read twice and referred to the Committee on the Judiciary.

    Senate

  2. Introduced in Senate

All available records shown.